disitamab vedotin + sintilimab + capecitabine

This combination therapy is a neoadjuvant regimen being investigated for the treatment of locally advanced HER2-expressing rectal cancer. It consists of three primary components: disitamab vedotin, sintilimab, and capecitabine. Disitamab vedotin (RC48) is a HER2-directed antibody-drug conjugate (ADC) that utilizes a humanized anti-HER2 antibody conjugated to the cytotoxic microtubule inhibitor monomethyl auristatin E (MMAE) via a cleavable linker. Sintilimab is a humanized monoclonal antibody that acts as a checkpoint inhibitor by blocking the programmed cell death protein 1 (PD-1) pathway, thereby restoring T-cell anti-tumor activity. Capecitabine is an oral fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an antimetabolite that inhibits DNA synthesis. The regimen is typically administered following neoadjuvant short-course radiotherapy to provide a multi-modal attack on tumor cells through targeted cytotoxicity, immune activation, and inhibition of cell proliferation.

Brand names

AidixiTyvytXeloda

Other names

RC48-ADCRC-48-ADCRC 48-ADCsintilimabcapecitabine